Pharmaceuticals

Rafael-B

Rafael-B 在 2026 年 6 月 11 日 (美东时间) 发布了 FY2026 前 9 个月业绩，实际营收 630 K USD，实际 EPS -0.4042 USD

Rafael-B 在 2026 年 6 月 11 日 (美东时间) 发布了 FY2026 Q3 业绩，实际营收 179 K USD，实际 EPS -0.0824 USD

Rafael-B released FY2026 Semi-Annual earnings on March 16 (EST), actual revenue USD 451K, actual EPS USD -0.32

Rafael-B released FY2026 Q2 earnings on March 16 (EST), actual revenue USD 211K, actual EPS USD -0.1299

Rafael-B released FY2026 Q1 earnings on December 11 (EST), actual revenue USD 240 K, actual EPS USD -0.1917

Rafael-B released FY2025 Q4 earnings on October 29 (EST), actual revenue USD 350 K, actual EPS USD -0.283

Rafael-B released FY2025 Annual Earnings on October 29 (EST), with actual revenue of USD 917K and EPS of USD -1.04

Raphael Holdings Short Interest Plummets

Rafael-B released FY2025 9 Months earnings on June 11 (EST), actual revenue USD 567K, actual EPS USD -0.7557

Rafael-B released FY2025 Q3 earnings on June 11 (EST), actual revenue USD 362K, actual EPS USD -0.1893

Rafael-B released FY2025 Q2 earnings on March 13 (EST), actual revenue 77K USD, actual EPS -0.1921 USD

Rafael-B released FY2025 Semi-Annual Earnings on March 13 (EST), actual revenue USD 205K, actual EPS USD -0.5699

Rafael-B released FY2025 Q1 earnings on December 11, 2024 (EST) with actual revenue of 128,000 and EPS of -0.3742

Rafael-B released FY2024 Annual Earnings on November 7, 2024 (EST), with actual revenue of USD 637K and EPS of USD -1.4499

Rafael-B released FY2024 Q4 earnings on November 7, 2024 (EST), actual revenue USD 165K, actual EPS USD -0.1876

Rafael-B released FY2024 9 Months Earnings on June 14, 2024 (EST), with actual revenue of 472,000 and EPS of -1.2644

Rafael-B released FY2024 Q1 earnings on December 14, 2023 (EST), with actual revenue of 68,000 and EPS of -0.1538

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Earning Release

业绩披露

2026.06.11 (EST) Announced FY2026 9M Earning Release (USD) Revenue 630 K, Net Income -20.46 M, EPS -0.4042

Rafael Holdings shares are trading higher. The company reported Q3 financial results.

benzinga_article

Rafael Holdings reported Q3 2026 revenue of $179K, down 50.6% YoY, with a net loss of $4.23M and diluted EPS of ($0.08). The company advanced its lead candidate Trappsol Cyclo into Phase 3 trials for NPC1 and received FDA clearance for the VECTR System. R&D spending increased to support clinical development, while management evaluates non-core assets to focus on strategic therapeutic investments.

TradingView

Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary

Rafael Holdings reported a Q3 FY2026 net loss of $4.2 million ($0.08/share) with $30.5M in cash and $0.18M revenue. R&D expenses were $4.9M. The pivotal Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 reached last patient last visit. Management expects to submit a New Drug Application (NDA) in H2 2026 following a pre-NDA meeting with the FDA, aiming to transition into a commercial-stage biotechnology company.

Cyclo Therapeutics

Rafael Holdings reports Q3 FY2026 net loss of $4.2M; cash $30.5M; NDA expected H2 2026

Earnings Watch

Rafael-B | 8-K: FY2026 Q3 Revenue: USD 179 K

Rafael Holdings reported Q3 FY2026 results ending April 30, 2026. The company recorded a net loss of $4.2 million ($0.08/share), compared to $4.8 million in the prior year period, with increased R&D expenses due to Cyclo Therapeutic consolidation. Cash and equivalents stood at $30.5 million. Clinically, Rafael completed the last patient visit for its pivotal Phase 3 TransportNPC™ trial and expects to submit an NDA to the FDA in H2 2026.

StockTitan

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results | RFL Stock News

Rafael Holdings announced the completion of the last patient visit for its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C. Topline results are expected in H2 2026, with an NDA submission planned for the same period following a pre-NDA meeting with the FDA. The company also noted positive data from a pediatric sub-study and acknowledged FDA approval to proceed with its Expanded Access Program.

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C | RFL Stock News

Rafael-B(RFL.US)